Arbutus Biopharma (ABUS) Earns Daily Media Impact Score of -0.04

Media coverage about Arbutus Biopharma (NASDAQ:ABUS) has trended somewhat negative recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arbutus Biopharma earned a media sentiment score of -0.04 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 46.0755822620664 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

A number of equities analysts recently commented on ABUS shares. Zacks Investment Research upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. ValuEngine cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a research report on Wednesday, October 25th. Leerink Swann reissued a “market perform” rating and issued a $5.00 price target (up from $4.00) on shares of Arbutus Biopharma in a research report on Tuesday, November 7th. BidaskClub cut shares of Arbutus Biopharma from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 14th. Finally, Chardan Capital reissued a “buy” rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. Arbutus Biopharma currently has an average rating of “Hold” and a consensus target price of $12.50.

Shares of Arbutus Biopharma (NASDAQ ABUS) opened at $5.05 on Friday. Arbutus Biopharma has a 1 year low of $2.45 and a 1 year high of $8.25. The firm has a market cap of $280.77 and a price-to-earnings ratio of -1.02. The company has a quick ratio of 11.03, a current ratio of 11.03 and a debt-to-equity ratio of 0.08.

Arbutus Biopharma (NASDAQ:ABUS) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The company had revenue of $6.90 million during the quarter, compared to analysts’ expectations of $0.79 million. equities analysts predict that Arbutus Biopharma will post -1.26 EPS for the current year.

WARNING: “Arbutus Biopharma (ABUS) Earns Daily Media Impact Score of -0.04” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at

Arbutus Biopharma Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit